Eco Animal Health Group Plc

IC say sell (266p): 04.08.06: -8, (275) IC say sell (266p): BEAR POINTS Shares highly rated - Dividend not covered by earnings -Risk of delays to approval... read more

IC say sell (266p): 04.08.06: -8, (275) IC say sell (266p): BEAR POINTS Shares highly rated - Dividend not covered by earnings -Risk of delays to approval programme BULL POINTS Sales forecast to grow rapidly - Potential for new uses of existing drugs

IC say buy (218p) - BULL POINTS Strong product range - All divisions are performing well - Aivlosin is more efficient than rivals - By 2007, sales at its Eco division could top $300m BEAR POINTS Delays in registrations will hold back sales - The shares are tightly held: - it remains dependent on the timing of registration wins, but there is still huge potential for growth at Lawrence. With a market... read more

IC say buy (218p) - BULL POINTS Strong product range - All divisions are performing well - Aivlosin is more efficient than rivals - By 2007, sales at its Eco division could top $300m BEAR POINTS Delays in registrations will hold back sales - The shares are tightly held: - it remains dependent on the timing of registration wins, but there is still huge potential for growth at Lawrence. With a market capitalisation of ?57m and minimal debt, the group is trading on 11 times operating cash flow and a forward earnings multiple of 17 times. This is a good business and the shares are worth buying, the journal says.

IC say Biu (159p) - BULL POINTS The demerger of Interpet will enhance group focus - Potential for massive growth at Eco - BEAR POINTS Delays in drug approvals would slow progress - Shares are tightly held by founding family: the main reasons for investing in animal health group Lawrence are the potential for a lucrative demerger of pet accessories provider... read more

IC say Biu (159p) - BULL POINTS The demerger of Interpet will enhance group focus - Potential for massive growth at Eco - BEAR POINTS Delays in drug approvals would slow progress - Shares are tightly held by founding family: the main reasons for investing in animal health group Lawrence are the potential for a lucrative demerger of pet accessories provider Interpet, and the growing number of drug approvals given to its 50 per cent-owned subsidiary, Eco Animal Health. Increased focus on Eco will drive Lawrence forwards, while it remains profitable, cash-generative and is debt-free. Based on a number of assumptions, including Eco selling $200m of 50 per cent margin Ecomectin and Aivlosin, broker Charles Stanley suggests that the long term value of Lawrence?s drug business alone would be 550p a share.

IC say buy (151p) - The market has responded to positive broker reports, good results and a selling-down of the majority family... read more

IC say buy (151p) - The market has responded to positive broker reports, good results and a selling-down of the majority family holding. Durlacher expects full-year profits of ?4m, with EPS of 12p. After a bonus share issue, the shares - currently 151p - are ahead of the equivalent 135p we recommended them at (28 March 2002).